Clinical trials: Secondary Progressive Multiple Sclerosis
Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting
Intermittent Hypoxia in Persons With Multiple Sclerosis
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06276634
- Testing
- Acute Intermittent Hypoxia
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Shirley Ryan AbilityLab
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Motor Asymmetry in Progressive Multiple Sclerosis Patients
Project Rational A better understanding of the causes of physical disability is an important unmet need in progressive Multiple Sclerosis patients.
- Trial name
- MAP-MS (NCT04918225)
- Testing
- Magnetic Resonance Imaging, Neurological examination, Multiple Sclerosis Functional Composite
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Secondary Progressive Multiple Sclerosis (SPMS)
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to know if rituximab can improve cognitive and hand functions in secondary progressive multiple sclerosis (SPMS) patients with high disability (EDSS 6.5 or more).
- Trial name
- NCT06599307
- Testing
- Rituximab
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Cairo University
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NACPMS (NCT05122559)
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Emmanuelle Waubant, MD PhD
Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity.
- Conditions
- Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
- Trial name
- NCT07426991
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in Germany
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06138132
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06390930
- Testing
- Acute Intermittent Hypoxia
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Shirley Ryan AbilityLab
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
The Synergistic Effects of AIH and FES in Persons With MS
The purpose of this study is to examine how neuromuscular electrical stimulation (NMES), may synergistically enhance corticospinal excitability in people with relapsing form multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06413602
- Testing
- Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shirley Ryan AbilityLab
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Home Based Functional Balance Intervention for Multiple Sclerosis
The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- HomeFBIinMS (NCT07355387)
- Testing
- Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance., Stretching
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Illinois at Chicago
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06526364
- Testing
- All participants will be asked to provide data and samples for collection and analysis.
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Sclerosis (MS) Secondary Progressive
Senolytics for Secondary Progressive MS
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities.
- Trial name
- NCT07270120
- Testing
- Dasatinib and quercetin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University
Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
- Trial name
- NCT04940065
- Testing
- Kesimpta
- Where
- 103 sites in Japan
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
The goal of this observational study is to validate a novel, cost-effective method for real-world assessment using patient-acquired "selfie" videos in people with multiple sclerosis.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, MS (Multiple Sclerosis)
- Trial name
- NCT07222618
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Francisco
Secondary Progressive Multiple Sclerosis
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia.
- Trial name
- EMBOSSES (NCT07168694)
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
Multiple sclerosis (MS) is a central nervous system inflammatory disease that causes a chronic and progressive physical handicap.
- Trial name
- SEPIA (NCT03471338)
- Testing
- Cognitive rehabilitation, Standard Psychological care
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Caen
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Treatment in Progressive Multiple Sclerosis
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
- Trial name
- NCT05349474
- Testing
- Metformin 500 Mg Oral Tablet, up to 4 tablets a day
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, Los Angeles
Non-relapsing Secondary Progressive Multiple Sclerosis
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic…
- Trial name
- HERCULES (NCT04411641)
- Testing
- Tolebrutinib
- Where
- 306 sites in United States, Argentina and 29 more
- Volunteers
- 1,131 people
- Sponsor
- Sanofi
Secondary Progressive Multiple Sclerosis
Simvastatin in Secondary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a neurological condition which is a common cause of disability in young people. It is thought to be an autoimmune condition, where the body's immune system begins to attack itself.
- Trial name
- MS-OPT (NCT03896217)
- Testing
- Simvastatin
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University College, London
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
This clinical trial aims to demonstrate that metformin can prevent clinical disability in patients with progressive MS by stopping or slowing down neurodegeneration by enhancing endogenous remyelination.
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
- Trial name
- NCT05893225
- Testing
- Metformin Hydrochloride 850 mg Oral Tablet
- Where
- 5 sites in Belgium
- Volunteers
- 120 people
- Sponsor
- University Hospital, Antwerp